The better the efficacy of a systemic treatment, the higher the patient satisfaction, especially if the risk-benefit balance is favorable. This plausible correlation is impressively underpinned by current findings from psoriasis research. In view of the wide range of treatments available, it is becoming increasingly important to select therapies that are tailored to individual patient characteristics. Analyses of the PsoBest registry and data sets from the “Adelphi Real World PsO Disease Specific Program” as well as other registry studies and survey data provide valuable insights in this regard.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Study report
Asthma exacerbation risk in patients with a psychological comorbidity
- Neuropathies - CIDP
Differentiate chronic inflammatory demyelinating polyneuropathy (CIDP)
- Treatment of type 2 diabetes: paradigm shift continues
Cardiorenal organ protection is increasingly coming to the fore
- Semaglutide and tirzepatide in HFpEF and T2D/obesity
Prospect of improved cardiovascular prognosis
- Case report: alveolar sarcoidosis
Acute hypoxemic respiratory failure as initial manifestation
- "Swiss Health Care Atlas"
Supply situation in Switzerland: Update
- Lung cancer
Multidisciplinary teams in oncology
- Adrenogenital syndrome